An employee examines vials of adrenaline hydrochloride injection solution at a China Grand Pharmaceutical and Healthcare Holdings Ltd. facility in Wuhan, China. (Photographer: Qilai Shen/Bloomberg)
(Bloomberg Businessweek) -- Western companies last year began selling some of their hottest cancer drugs, called PD-1 inhibitors, with much fanfare in China. But rather than quickly conquering the mainland market, American drugmakers Merck & Co. and Bristol-Myers Squibb Co. have found themselves facing a surprising challenge: local competitors. Chinese companies are introducing patented cancer therapies in their home market based on ...